Missing out on effective care in idiopathic pulmonary fibrosis: Racial inequality in access to anti-fibrotic therapy

被引:0
|
作者
Pascoe, Amy [1 ]
Smallwood, Natasha [1 ,2 ]
机构
[1] Monash Univ, Cent Clin Sch, Resp Res, Alfred, Vic, Australia
[2] Alfred Hosp, Dept Resp & Sleep Med, Prahran, Vic, Australia
关键词
antifibrotic agents; health disparities; health inequities; idiopathic pulmonary fibrosis; interstitial lung disease; mortality; social determinants of health; DISPARITIES; COPD;
D O I
10.1111/resp.14594
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
See related article
引用
收藏
页码:978 / 979
页数:2
相关论文
共 50 条
  • [31] Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis
    Sugino, Keishi
    Shimizu, Hiroshige
    Nakamura, Yasuhiko
    Isshiki, Takuma
    Matsumoto, Keiko
    Homma, Sakae
    JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 899 - 908
  • [32] A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
    Shah, Parth, V
    Balani, Prachi
    Lopez, Angel R.
    Nobleza, Chelsea Mae N.
    Siddiqui, Mariah
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (01)
  • [33] Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin
    Papakonstantinou, Eleni
    Klagas, Ioannis
    Bonovolias, Ioannis
    Sun, Qingzhu
    Tamm, Michael
    Lambers, Christopher
    Roth, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [34] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
    Sugino, Keishi
    Ono, Hirotaka
    Saito, Mikako
    Ando, Masahiro
    Tsuboi, Eiyasu
    PLOS ONE, 2024, 19 (06):
  • [35] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Hostettler, Katrin E.
    Zhong, Jun
    Papakonstantinou, Eleni
    Karakiulakis, George
    Tamm, Michael
    Seidel, Petra
    Sun, Qingzhu
    Mandal, Jyotshna
    Lardinois, Didier
    Lambers, Christopher
    Roth, Michael
    RESPIRATORY RESEARCH, 2014, 15
  • [36] Effects of Anti-Fibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis
    Ishii, Daisuke
    Kawasaki, Takeshi
    Sato, Hironori
    Tatsumi, Koichiro
    Imamoto, Takuro
    Yoshioka, Keiichiro
    Abe, Mitsuhiro
    Hasegawa, Yoshinori
    Ohara, Osamu
    Suzuki, Takuji
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [37] Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
    Katrin E Hostettler
    Jun Zhong
    Eleni Papakonstantinou
    George Karakiulakis
    Michael Tamm
    Petra Seidel
    Qingzhu Sun
    Jyotshna Mandal
    Didier Lardinois
    Christopher Lambers
    Michael Roth
    Respiratory Research, 15
  • [38] Characteristics Of Patients With Idiopathic Pulmonary Fibrosis (ipf) Receiving Approved Anti-Fibrotic Therapies In The Us
    Gamerman, V.
    Salisbury, M.
    Culver, D.
    Leonard, T.
    Neely, M. L.
    Yow, E.
    Conoscenti, C. S.
    Palmer, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [39] Endostatin in fibrosis and as a potential candidate of anti-fibrotic therapy
    Zhang, Zequn
    Liu, Xi
    Shen, Zhaolong
    Quan, Jun
    Lin, Changwei
    Li, Xiaorong
    Hu, Gui
    DRUG DELIVERY, 2021, 28 (01) : 2051 - 2061
  • [40] Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing
    Burgess, Andrew
    Goon, Ken
    Brannan, John D.
    Attia, John
    Palazzi, Kerrin
    Oldmeadow, Christopher
    Corte, Tamera J.
    Glaspole, Ian
    Goh, Nicole
    Keir, Gregory
    Allan, Heather
    Chapman, Sally
    Cooper, Wendy
    Ellis, Samantha
    Hopkins, Peter
    Moodley, Yuben
    Reynolds, Paul
    Zappala, Chris
    Macansh, Sacha
    Grainge, Christopher
    RESPIROLOGY, 2019, 24 (10) : 988 - 995